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Abstract 
Background: Anthracycline therapy for acute leukemia may be associated with
significant morbidity and mortality in children or elderly patients that have a degree
of heart failure. Patients with prior anthracycline exposure, those with pre-existing
heart disease, or who have received the total anthracycline dose present an increased
risk for cardiotoxicity. Therefore, new chemotherapy regimens in these situations would
be life saving for leukemia patients. We have conducted a systematic review of possible
strategies for rescue regimens without anthracycline in refractory acute leukemia
patients.
Methods: We gathered the data from 5 creation databases and relevant website
until August 2016. We selected randomized clinical trials or other studies that used
anthracycline-free chemotherapy regimens to treat acute refractory leukemia in
children and adults. The quality of the studies was evaluated according to the
Cochrane risk of the polarization tool. All stages of the review were independently
conducted by two authors. We obtained data from 75 main clinical trials.
Results: There were 75 trials included from which 4 were considered to be at low
risk for bias. Most trials showed that the improvement did not reach statistical
significance.
Conclusion: Evidence existed to support the use of the combination of fludarabine,
cytarabine, and filgrastim, ICE-rituximab chemotherapy regimens, or monoclonal
antibodies such as tyrosine kinase inhibitors (Sorafenib) useful for acute
refractory/relapsed leukemia.These drugs are used as first salvage regimens or
clofarabine and cladribine for acute myeloid leukemia in patients for whom combined
anthracycline chemotherapy is inappropriate.
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Chemotherapy
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Introduction
Anthracyclines are one of the most effective
compounds in chemotherapy. The adverse effect
attributed to these drugs is cardiotoxicity that
develops into heart failure.1 With the aim to
maintain the cumulative dose in the normal range,
miscellaneous prevention processes can be
achieved by the pediatric oncologist to decrease
the risk of cardiotoxicity. Regular cardiac
monitoring and administration of dexrazoxane
and/or the use of a liposomal doxorubicin
preparation are effective methods prior to the full
cumulative dose.2
The selection of an effective, new
chemotherapy regimen poses a challenge in acute
leukemia patients that relapse following a full
cumulative dose of anthracyclines or in patients
with antracycline induced heart failure. Therefore,
it is necessary and challenging to find a
successional strategy instead of anthracyclines.
Establishing a balance between a prescribed
suboptimal chemotherapy dosage by the
oncologist and preventing relapse of acute
leukemia is a challenge. Several methods have
been used to reduce cardiotoxicity of the initial
exposure to anthracyclines to protect myocardial
function.3
Pediatric oncologists may administer another
chemotherapy regimen to leukemia patients with
heart disease, which is similar to elderly patients.
This appears to be a valuable outcome in pediatric
oncology, but this hypothesis should be explored
in a sufficient number of clinical trials.
In adults, new regimens administered based on
clofarabine,vosaroxin, sorafenib, fludarabine, and
cladribine may effectively replace anthracycline-
based regimens in pediatric patients that have
refractory/relapsed (R/R) leukemia. 
Materials and Methods
Search methods
We obtained data from Pubmed, Medline,
Embase, Google Scholar, and CINAHL from
August 1995 until August 2016, in addition to a
search of relevant websites. English language
papers were included and we collected expert
opinions or information from seminars such as the
American Society of Hematology annual
meetings, oral presentations, and abstract papers.
Selection criteria
This review included data from free
antracycline chemotherapy regimens for acute
refractory leukemia that used a controlled study
design (with or without randomization). We
included studies that evaluated interventions,
policies or programs in place for 12 weeks or
more. 
Inclusion criteria for selected articles consisted
of: publication date between 1995 and 2016;
article in English peer-reviewed journals; study
was done to minimize bias; identification of all
relevant studies; and sufficient similarities between
the selected studies to make combining them
reasonable.
Exclusion criteria consisted of: not published
as a full article (conference proceedings excluded);
published in a language other than English; the
studied population had underlying disorders except
for cancer; and systematic review if they were
meeting abstracts not subsequently published in
peer-reviewed journals, editorials, commentaries,
letters, news articles, case reports, or narrative
reviews.
Two review authors independently extracted
data and assessed the risk of bias for the included
studies.  
Main results
Clinical questions of this review included the
following question. What chemotherapy regimens
are appropriate for refractory relapsed acute
leukemia patients with antracycline induced
cardiac toxicity? 
The research team developed a study protocol
to address research questions for the pediatric
patient population with acute leukemia. The
review included additional studies and related
studies found for this update based on the
following key words:
“Refractory relapsed acute leukemia AND
antracycline free chemotherapy regimens” (10/50),
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where the first number was the number of located
articles. The second was the number of related
articles. Next, we found a number of drugs for
recurrent refractory acute leukemia that were the
basis for chemotherapy-free anthracycline
regimens, such as: vosaroxin, cytarabine,
fludarabine, clofarabine, cladribine, sorafenib,
and the ICE protocol.
“refractory relapsed acute leukemia vosaroxin
plus cytarabine” (3/12)
“refractory relapsed acute leukemia AND
cytarabine ” (30/95)
“refractory relapsed acute leukemia AND
fludarabine ” (34/66)
“refractory relapsed acute leukemia AND
clofarabine ” (25/56)
“refractory relapsed acute leukemia AND
cladribine ” (33/45)
“refractory relapsed acute leukemia AND ICE
protocol ” (2/10)
“refractory relapsed acute leukemia AND
sorafenib ” (24/45)
All studies were screened for children aged 0-
18 years or weak elderly adult patients. Review
articles included 19 studies of “acute leukemia
AND anthracycline free chemotherapy regimens”
in children and antracycline free chemotherapy
regimens, although the observed heterogeneity
rate was high (I2=82%).
We observed heterogeneity in both age groups
(adult and pediatric) that could not be explained
by the status of randomization or the type,
duration, or extent of the intervention.
We found strong evidence that supported the
beneficial effects of some chemotherapy drugs
which could replace anthracyclines such as rescue
or salvage plans in acute leukemia in adults.
However, because of unexplained heterogeneity
and probability of a low bias study, these results
should be interpreted with caution. A wide range
of program components were used in these studies,
although it was impossible to distinguish which
of these components had the most contribution to
the observed beneficial effects. Our synthesis
indicated the following promising policies and
strategies. In the final review we selected 13
articles. Their main results are presented in the
references.
Results
We included a total of 75 trials; 4 were
considered to be at low risk for bias. Most trials
showed that the improvement did not reach
statistical significance.
Sorafenib-based regimen
Sorafenib tosylate is a synthetic compound
that targets growth signaling and angiogenesis. It
affects the critical component of the
RAF/MEK/ERK signaling pathway that controls
cell division and proliferation. Sorafenib blocks
the enzyme RAF kinase. In addition, sorafenib
inhibits the VEGFR-2/PDGFR-beta signaling
cascade and, as a result, blocks tumor
angiogenesis. Sorafenib with low-dose cytarabine
in patients with heart failure is used for R/R acute
leukemia.4-7
Sorafenib, as a FLT3-ITD inhibitor drug, is
an effective treatment in patients with acute
myeloid leukemia (AML) and myelodysplastic
syndrome (MDS) with the FLT3-ITD mutation .
Patients should receive subcutaneous
administration of cytarabine (10 mg/m2 bid) on
days 1-10 and oral sorafenib tosylate at doses of
200-600 mg/1.73 m2 bid on days 2-28. Sorafenib
tosylate is added to salvage chemotherapy
regimens as a targeted therapy. The anti-leukemic
effects of sorafenib and azacytidine have been
evaluated in FLT3-ITD + cell lines in vitro.
Sorafenib and azacitidine showed synergistic
inhibition of cell proliferation and apoptosis
induction. Subsequently, consolidation azacitidine
(100 mg/day × 4 days) subcutaneously every four
weeks until disease progression or allogeneic
Hematopoetic stem cell transplantation was
administered. The total dose of 400 mg per cycle
was similar to that used for the maintenance of
AML. A 4-day decision-making scheme was
practical to avoid wasting medicines and to shorten
the duration of administration.8-11 
Vosaroxin-based regimens
Vosaroxin, is a quinolone-derived intercalating
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agent. Initial clinical studies have shown that it is
well-tolerated in weak patients with R/R acute
leukemia. A synergistic effect with cytarabine
(Ara-C) must be considered. Vosaroxin is
administered at 90 mg/m2 intravenously on days
1 and 4 in the first cycle, followed by 70 mg/m2
in subsequent cycles, and cytarabine (1 g/m2,
intravenously on days 1-5). 
Vosaroxina has shown reliable results when
combined with cytarabine and might be of clinical
benefit to some patients with R/R AML. In elderly
patients with acute R/R AML, the situation is
similar to pediatric patients with heart failure.12-20
Clofarabine-based regimen
Clofarabine is a second generation purine
nucleoside analog designed to overcome the
limitations and incorporate the best qualities of
cladribine and fludarabine. Clofarabine enters the
cells by passive transport through lipid
membranes, as well as the transport of active
nucleosides.  Unlike cladribine, clofarabine is
active in both AML and ALL. Although cladribine
was not active in adult leukemia and induced
neurotoxicity in this population, clofarabine
showed activity in adult leukemia and did not
induce the neurotoxicity associated with other
nucleoside analogs. One patient with AML who
received clofarabine monotherapy remained in
complete remission for 43 weeks without therapy.
Once inside the cell, clofarabine is phosphorylated
to its active triphosphate form by cellular kinases,
including deoxycytidine kinase. While fludarabine
and cladribine only inhibit ribonucleotide
reductase and DNA polymerase, respectively,
clofarabine inhibits both enzymes.22-24
In some regimens, the efficacy and safety of
administration of intravenous clofarabine (40
mg/m2), cyclophosphamide (440 mg/m2), and
etoposide (100 mg/m2) for 5 consecutive days in
R/R pediatric patients showed encouraging
response rates and sustained remission in R/R
patients.25-28
In addition, daily intravenous clofarabine (20
mg/m2) administration for 5 days and cytarabine
(20 mg subcutaneously) twice daily for 10 days
is an effective regimen. Clofarabine with low
dose of alternate cytarabine and decitabine in
consolidation phase is effective in newly
diagnosed AML patients with heart conditions.
It seems these regimens are an appropriate
approach for first treatment in refractory AML in
patients who cannot receive anthracycline. The
benefits of prolonged consolidation remain
unproven. Additional randomized controlled trials
are needed to directly compare the efficacy of
clofarabine as a single agent and in combination
therapy compared with intensive chemotherapy
regimens.30-34
Fludarabin-based regimen 
Fludarabine phosphate is 2-fluoro, a 5'-
monophosphate derivative of vidarabine (Ara-A)
with improved solubility. The mechanism of
cytotoxic action of the compound appears to
involve the metabolic conversion of the active
triphosphate.35,36
Fludarabine has a substantial activity against
lymphoid malignancies. The most popular regimen
against lymphoid malignancies is the FLAG
protocol that includes two fludarabine 30
mg/m2/day + Ara-C 2 g/m2/day for days 1-5 and
G-CSF (5 mcg/kg/day) from day 0 to recovery of
polymorphonuclear cells. Elderly patients with
untreated AML are administered FLAG as initial
induction chemotherapy at some adult centers.
Primary induction with FLAG in elderly AML
patients achieves a high remission rate without
prohibitive mucosal or cardiac toxicity and may
be considered as an alternative to standard
anthracycline-based regimens in this setting.
The FLAG regimen is a non-anthracycline
based regimen that may serve as an alternative to
the standard induction regimens for AML in older
adults or those with significant co-morbidities
that include preexisting cardiac disease. It is
associated with comparable remissio n rates and
acceptable overall survival in older patients. In
addition, it may allow some patients with
preexisting cardiac disease to proceed to allo-
SCT.43-47
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ICE-rituximab regimen
Rituximab (375 mg/m2) was administered on
days 1 and 3 of each cycle, ifosfamide (3000
mg/m2) and etoposide (100 mg/m2) administered
on days 3, 4 and 5, and carboplatin (635 mg/m2)
administered only on day 3.48-50 ICE-rituximab is
administered for 1 to 3 cycles depending on the
response.
The combination of rituximab and ICE
chemotherapy have safe, acceptable toxicity. At
the end of the protocol, some patients could
possibly proceed to consolidation with high dose
therapy and stem cell rescue. This chemotherapeu-
tic regimen, without the use of an anthracycline
drug, has an outcome comparable to other
regimens for adult acute leukemia. These regimens
were well-tolerated by several ranges patients
with acute leukemia, including pediatric patients.
The ICE protocol combined with rituximab in
childhood Burkitt’s leukemia in patients with
poor prognoses is useful.51
Cladribine (2-CdA)-based regimen
Cladribine (2-CdA) is an adenosine deaminase
resistant analog of adenosine induce apoptosis
of myeloid cells. 2-CdA has activity in R/R
myeloid neoplasms such as pediatric AML with
a complete response (CR) rate of 47%. Several
studies have confirmed the efficacy of single
agent 2-CdA or 2-CdA combination regimens in
AML. Established CR rates for combination
regimens in R/R adults were approximately 50%,
while CR rates for ND adults were approximately
70% and showed similar toxicity profiles to
previously used regimens. Despite these promising
data, many centers have yet to adopt 2-CdA
combination regimens for these difficult-to-treat
populations.52-55
Cladribine with cytarabine (Ara-C) and G-
CSF (CLAG regimen), and re-induction therapy
were administered in patients with R/R AML.
The protocol consisted of 2-CdA (5 mg/m2 for 2
hours of infusion per day) for 5 consecutive days.
A 4-hour infusion of Ara-C (2 g/m2) for 2 hours
was administered after each 2-CdA infusion. G-
CSF (300 microgram) was administered 24 hours
prior to the first dose of 2-CdA for 6 days.
In patients with CR, the consolidation treatment
begins with a treatment that contains 2-CdA.56-60
The CLAG regimen has shown significant anti-
leukemia activity and acceptable toxicity as
reinduction treatment in R/R AML patients. This
regimen, CLAG-M, is a well-tolerated, highly
effective salvage regimen in poor risk R/R AML.
In primary refractory disease, CR was 45.5% for
CLAG.61-63
Conclusion
Development of an experimental regimen in
R/R pediatric acute leukemia remains a clinical
challenge, especially without anthracyclines.
Evidence exists to support the use of FLAG
chemotherapy. ICE-rituximab regimens or
monoclonal antibodies such as tyrosine kinase
inhibitors (Sorafenib) or clofarabine, cladribine are
non-anthracycline agents useful for acute R/R
leukemia as a first salvage treatment among AML
patients that cannot use anthracyclines..
In the absence of a common therapeutic
approach, physicians should compare all currently
available methods, including chemotherapy-free
anthracycline regimens, targeted therapy, and
allogeneic HSCT, or a combination of these as a
life-saving options for R/R acute leukemia.
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